Results 91 to 100 of about 7,902 (191)
Luis M RuilopeUnidad de Hipertensión, Hospital 12 de Octubre, Madrid, SpainAbstract: Hypertension is a major risk factor for cardiovascular disease that contributes to the premature death of millions of people each year, and identification and ...
Luis M Ruilope
doaj
Severe Hepatitis Complicating Olmesartan Enteropathy: A Case Report
Introduction: Olmesartan, an angiotensin II receptor antagonist, is associated with an uncommon complication of enteropathy that presents insidiously, usually months to years after initial commencement of anti-hypertensive therapy which can be dose ...
Ruyi Tan +5 more
doaj +1 more source
Philipp Sievers,1 Lorenz Uhlmann,2 Sevil Korkmaz-Icöz,3 Christian Fastner,1 Florian Bea,1 Erwin Blessing,1 Hugo A Katus,1 Michael R Preusch11Department of Internal Medicine III, 2Institute of Medical Biometry and Informatics, 3Department of ...
Katus HA +7 more
core
Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil
BACKGROUND: The orally active, nonpeptide antagonists of the angiotensin II subtype 1 (AT1) receptor represent a recent class of antihypertensive drugs that selectively block the renin-angiotensin system. Olmesartan medoxomil is the newest member of this
Koike H +5 more
core +1 more source
Angioprotection role in arterial hypertension treatment: focus on olmesartan
The paper discusses the role of organoprotection in arterial hypertension treatment. The results of international studies on effectiveness of olmesartan, a modern angiotensin II receptor antagonist, are presented. The available evidence confirms not only
D. V. Nebieridze +3 more
doaj +1 more source
Systematic review: Sprue-like enteropathy associated with olmesartan
The onset of a sprue-like enteropathy in association with olmesartan therapy has been recently ...
Montalto, Massimo +3 more
core +2 more sources
Severe Spruelike Enteropathy Associated With Olmesartan
Objective: To report the response to discontinuation of olmesartan, an angiotensin II receptor antagonist commonly prescribed for treatment of hypertension, in patients with unexplained severe spruelike enteropathy.Patients and Methods: All 22 patients ...
Mangan, Thomas F., +13 more
core +1 more source
The pharmacoeconomic analysis compared the strategies of arterial hypertension (AH) management using different angiotensin II receptor blockers (ARB). The first stage of the analysis included the cost-effectiveness modelling in patients with moderate AH ...
S. G. Gorokhova, V. V. Ryazhenov
doaj
Seronegative Intestinal Villous Atrophy: A Diagnostic Challenge
Celiac disease is the most important cause of intestinal villous atrophy. Seronegative intestinal villous atrophy, including those that are nonresponsive to a gluten-free diet, is a diagnostic challenge.
Cláudio Martins +10 more
doaj +1 more source
The aim of the present work was to review published studies, investigating the dose-related efficacy on blood pressure (BP) of olmesartan and of other commercially available angiotensin II type I receptor blockers (ARBs).
Faiez Zannad, Renaud Fay
doaj

